Hardrock Seismic Reflection Through Cover: Defining Controls on Mineralization via Reflection Attribute Analysis

This study attempts to modify oil and gas industry seismic processing and interpretation techniques for use in Carlin-type deposit (CTD) gold exploration. Magmatic and deformation overprints on the Nevada carbonate platform-slope setting present challenges in seismic interpretation when compared to conventional seismic data, which is more commonly imaged in petroliferous basins with low levels of deformation. Barrick Gold Corporation provided 2D seismic reflection data for this case study, which assesses the viability of certain seismic practices when applied to hardrock seismic data collected in NE Nevada. Initial seismic interpretations of the pre-stack depth migrated (PSDM) sections located first-order structures and enhanced the geological model. This study uses derivatives of the PSDM, called seismic attributes, in an attempt to improve interpretability. Seismic attributes can reveal structural and stratigraphic features that are not apparent in the conventional PSDM amplitude data. Attribute analysis in this study leverages correlations made from a seismic response database of ~500 petrophysical drill core samples. These petrophysical measurements indicate that the ore zone exhibits a porosity, acoustic impedance, decarbonatization relationship that is distinguishable from unaltered rock. Down-hole geophysical data suggest an even larger contrast between altered and unaltered limestone. Given sufficient data quality, these observations make attribute analysis for detection of CTD alteration viable. An exhaustive calculation of attributes applied to one 2D reflection profile, which transects the Goldrush CTD resource, suggests that energy- and frequency-based attributes best highlight the ore zone, which is expressed as a chaotic zone of reduced amplitude within one 2D profile. RMS amplitude and instantaneous amplitude identify broad zones of low amplitude whereas an average frequency attribute highlights possible high-frequency attenuation effects in the vicinity of the ore-zone. The sweetness and frequency washout attributes combine frequency and amplitude attributes to more effectively highlight the ore zone. However, the erratic response of sweetness and frequency washout suggest that they may be negatively affected by noise. One structural model is also presented, which used the instantaneous phase attribute to better visualize possible thrust faulting

A new automatic method to identify galaxy mergers - I. Description and application to the Space Telescope A901/902 Galaxy Evolution Survey

We present a new automatic method to identify galaxy mergers using the morphological information contained in the residual images of galaxies after the subtraction of a smooth Sérsic model. The removal of the bulk signal from the host galaxy light is done with the aim of detecting the much fainter and elusive minor mergers. The specific morphological parameters that are used in the merger diagnostic suggested here are the residual flux fraction (RFF) and the asymmetry of the residuals [A(Res)]. The new diagnostic has been calibrated and optimized so that the resulting merger sample is very complete. However, the contamination by non-mergers is also high. If the same optimization method is adopted for combinations of other structural parameters such as the Concentration, Asymmetry, clumpineSs (CAS) system, the merger indicator we introduce yields merger samples of equal or higher statistical quality than the samples obtained through the use of other structural parameters. We investigate the ability of the method presented here to select minor mergers by identifying a sample of visually classified mergers that would not have been picked up by the use of the CAS system, when using its usual limits. However, given the low prevalence of mergers among the general population of galaxies and the optimization used here, we find that the merger diagnostic introduced in this work is best used as a negative merger test, that is, it is very effective at selecting non-merging galaxies. In common with all the currently available automatic methods, the sample of merger candidates selected is heavily contaminated by non-mergers, and further steps are needed to produce a clean merger sample. This merger diagnostic has been developed using the Hubble Space Telescope/ACS F606W images of the A901/902 multiple cluster system (z= 0.165) obtained by the Space Telescope A901/902 Galaxy Evolution Survey team. In particular, we have focused on a mass- and magnitude-limited sample (log M/M⊙ > 9.0, RVega, Total≤ 23.5 mag) which includes 905 cluster galaxies and 655 field galaxies of all morphological type

A New Automatic Method to Identify Galaxy Mergers I. Description and Application to the STAGES Survey

We present an automatic method to identify galaxy mergers using the morphological information contained in the residual images of galaxies after the subtraction of a Sersic model. The removal of the bulk signal from the host galaxy light is done with the aim of detecting the fainter minor mergers. The specific morphological parameters that are used in the merger diagnostic suggested here are the Residual Flux Fraction and the asymmetry of the residuals. The new diagnostic has been calibrated and optimized so that the resulting merger sample is very complete. However, the contamination by non-mergers is also high. If the same optimization method is adopted for combinations of other structural parameters such as the CAS system, the merger indicator we introduce yields merger samples of equal or higher statistical quality than the samples obtained through the use of other structural parameters. We explore the ability of the method presented here to select minor mergers by identifying a sample of visually classified mergers that would not have been picked up by the use of the CAS system, when using its usual limits. Given the low prevalence of mergers among the general population of galaxies and the optimization used here, we find that the merger diagnostic introduced in this work is best used as a negative merger test, i.e., it is very effective at selecting non-merging galaxies. As with all the currently available automatic methods, the sample of merger candidates selected is contaminated by non-mergers, and further steps are needed to produce a clean sample. This merger diagnostic has been developed using the HST/ACS F606W images of the A901/02 cluster (z=0.165) obtained by the STAGES team. In particular, we have focused on a mass and magnitude limited sample (log M/M_{O}>9.0, R_{Vega}<23.5mag)) which includes 905 cluster galaxies and 655 field galaxies of all morphological types.Comment: 25 pages, 14 figures, 4 tables. To appear in MNRA

Skull base erosion and associated complications in sphenoid sinus fungal balls

Background: Sphenoid sinus fungal balls (SSFB) are rare entities that can result in serious orbital and intracranial complications. There are few published reports of complications that result from SSFB. Objective: To review the incidence of skull base erosion and orbital or intracranial complications in patients who present with SSFB. Methods: A retrospective review was performed of all the patients with SSFB who were treated at the Massachusetts Eye and Ear Infirmary from 2006 to 2014. Presenting clinical data, radiology, operative reports, pathology, and postoperative course were reviewed. Results: Forty-three patients with SSFB were identified. Demographic data were compared between patients with (39.5%) and those without (61.5%) skull base erosion. Two patients underwent emergent surgery for acute complications of SSFB (one patient with blindness, one patient who had a seizure). Both patients with acute complications had evidence of skull base erosion, whereas no patients with an intact skull base developed an orbital or intracranial complication (p = 0.15). All the patients were surgically managed via an endoscopic approach. Conclusion: SSFBs are rare but may cause significant skull base erosion and potentially severe orbital and intracranial complications if not treated appropriately. Endoscopic sphenoidotomy is effective in treating SSFB and should be performed emergently in patients who presented with associated complications

The SDSS-III Baryon Oscillation Spectroscopic Survey: Quasar Target Selection for Data Release Nine

The SDSS-III Baryon Oscillation Spectroscopic Survey (BOSS), a five-year spectroscopic survey of 10,000 deg^2, achieved first light in late 2009. One of the key goals of BOSS is to measure the signature of baryon acoustic oscillations in the distribution of Ly-alpha absorption from the spectra of a sample of ~150,000 z>2.2 quasars. Along with measuring the angular diameter distance at z\approx2.5, BOSS will provide the first direct measurement of the expansion rate of the Universe at z > 2. One of the biggest challenges in achieving this goal is an efficient target selection algorithm for quasars over 2.2 < z < 3.5, where their colors overlap those of stars. During the first year of the BOSS survey, quasar target selection methods were developed and tested to meet the requirement of delivering at least 15 quasars deg^-2 in this redshift range, out of 40 targets deg^-2. To achieve these surface densities, the magnitude limit of the quasar targets was set at g <= 22.0 or r<=21.85. While detection of the BAO signature in the Ly-alpha absorption in quasar spectra does not require a uniform target selection, many other astrophysical studies do. We therefore defined a uniformly-selected subsample of 20 targets deg^-2, for which the selection efficiency is just over 50%. This "CORE" subsample will be fixed for Years Two through Five of the survey. In this paper we describe the evolution and implementation of the BOSS quasar target selection algorithms during the first two years of BOSS operations. We analyze the spectra obtained during the first year. 11,263 new z>2.2 quasars were spectroscopically confirmed by BOSS. Our current algorithms select an average of 15 z > 2.2 quasars deg^-2 from 40 targets deg^-2 using single-epoch SDSS imaging. Multi-epoch optical data and data at other wavelengths can further improve the efficiency and completeness of BOSS quasar target selection. [Abridged]Comment: 33 pages, 26 figures, 12 tables and a whole bunch of quasars. Submitted to Ap

Outer-Sphere Contributions to the Electronic Structure of Type Zero Copper Proteins

Bioinorganic canon states that active-site thiolate coordination promotes rapid electron transfer (ET) to and from type 1 copper proteins. In recent work, we have found that copper ET sites in proteins also can be constructed without thiolate ligation (called “type zero” sites). Here we report multifrequency electron paramagnetic resonance (EPR), magnetic circular dichroism (MCD), and nuclear magnetic resonance (NMR) spectroscopic data together with density functional theory (DFT) and spectroscopy-oriented configuration interaction (SORCI) calculations for type zero Pseudomonas aeruginosa azurin variants. Wild-type (type 1) and type zero copper centers experience virtually identical ligand fields. Moreover, O-donor covalency is enhanced in type zero centers relative that in the C112D (type 2) protein. At the same time, N-donor covalency is reduced in a similar fashion to type 1 centers. QM/MM and SORCI calculations show that the electronic structures of type zero and type 2 are intimately linked to the orientation and coordination mode of the carboxylate ligand, which in turn is influenced by outer-sphere hydrogen bonding

Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?

Purpose. The association between transarterial chemoembolization- (TACE-) induced HCC tumor necrosis measured by the modified Response Evaluation Criteria In Solid Tumors (mRECIST) and patient survival is poorly defined. We hypothesize that survival will be superior in HCC patients with increased TACE-induced tumor necrosis. Materials and Methods. TACE interventions were retrospectively reviewed. Tumor response was quantified via dichotomized (responders and nonresponders) and the four defined mRECIST categories. Results. Median survival following TACE was significantly greater in responders compared to nonresponders (20.8 months versus 14.9 months, p=0.011). Survival outcomes also significantly varied among the four mRECIST categories (p=0.0003): complete, 21.4 months; partial, 20.8; stable, 16.8; and progressive, 7.73. Only progressive disease demonstrated significantly worse survival when compared to complete response. Multivariable analysis showed that progressive disease, increasing total tumor diameter, and non-Child-Pugh class A were independent predictors of post-TACE mortality. Conclusions. Both dichotomized (responders and nonresponders) and the four defined mRECIST responses to TACE in patients with HCC were predictive of survival. The main driver of the survival analysis was poor survival in the progressive disease group. Surprisingly, there was small nonsignificant survival benefit between complete, partial, and stable disease groups. These findings may inform HCC treatment decisions following first TACE

US Cosmic Visions: New Ideas in Dark Matter 2017: Community Report

This white paper summarizes the workshop "U.S. Cosmic Visions: New Ideas in Dark Matter" held at University of Maryland on March 23-25, 2017.Comment: 102 pages + reference

Genetic Signatures of Exceptional Longevity in Humans

Like most complex phenotypes, exceptional longevity is thought to reflect a combined influence of environmental (e.g., lifestyle choices, where we live) and genetic factors. To explore the genetic contribution, we undertook a genome-wide association study of exceptional longevity in 801 centenarians (median age at death 104 years) and 914 genetically matched healthy controls. Using these data, we built a genetic model that includes 281 single nucleotide polymorphisms (SNPs) and discriminated between cases and controls of the discovery set with 89% sensitivity and specificity, and with 58% specificity and 60% sensitivity in an independent cohort of 341 controls and 253 genetically matched nonagenarians and centenarians (median age 100 years). Consistent with the hypothesis that the genetic contribution is largest with the oldest ages, the sensitivity of the model increased in the independent cohort with older and older ages (71% to classify subjects with an age at death>102 and 85% to classify subjects with an age at death>105). For further validation, we applied the model to an additional, unmatched 60 centenarians (median age 107 years) resulting in 78% sensitivity, and 2863 unmatched controls with 61% specificity. The 281 SNPs include the SNP rs2075650 in TOMM40/APOE that reached irrefutable genome wide significance (posterior probability of association = 1) and replicated in the independent cohort. Removal of this SNP from the model reduced the accuracy by only 1%. Further in-silico analysis suggests that 90% of centenarians can be grouped into clusters characterized by different “genetic signatures” of varying predictive values for exceptional longevity. The correlation between 3 signatures and 3 different life spans was replicated in the combined replication sets. The different signatures may help dissect this complex phenotype into sub-phenotypes of exceptional longevity

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease A Randomized Clinical Trial

Importance Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives and may therefore lead to stable systemic exposure while preserving key pharmacological activity. Objective To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. Design, Setting, and Participants Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea score of 8 or higher (range, 0-28; lower score indicates less chorea) were enrolled from August 2013 to August 2014 and randomized to receive deutetrabenazine (n = 45) or placebo (n = 45) in a double-blind fashion at 34 Huntington Study Group sites. Interventions Deutetrabenazine or placebo was titrated to optimal dose level over 8 weeks and maintained for 4 weeks, followed by a 1-week washout. Main Outcomes and Measures Primary end point was the total maximal chorea score change from baseline (the average of values from the screening and day-0 visits) to maintenance therapy (the average of values from the week 9 and 12 visits) obtained by in-person visits. This study was designed to detect a 2.7-unit treatment difference in scores. The secondary end points, assessed hierarchically, were the proportion of patients who achieved treatment success on the Patient Global Impression of Change (PGIC) and on the Clinical Global Impression of Change (CGIC), the change in 36-Item Short Form– physical functioning subscale score (SF-36), and the change in the Berg Balance Test. Results Ninety patients with Huntington disease (mean age, 53.7 years; 40 women [44.4%]) were enrolled. In the deutetrabenazine group, the mean total maximal chorea scores improved from 12.1 (95% CI, 11.2-12.9) to 7.7 (95% CI, 6.5-8.9), whereas in the placebo group, scores improved from 13.2 (95% CI, 12.2-14.3) to 11.3 (95% CI, 10.0-12.5); the mean between-group difference was –2.5 units (95% CI, –3.7 to –1.3) (P < .001). Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002). As measured by the CGIC, treatment success occurred in 19 patients (42%) in the deutetrabenazine group vs 6 (13%) in the placebo group (P = .002). In the deutetrabenazine group, the mean SF-36 physical functioning subscale scores decreased from 47.5 (95% CI, 44.3-50.8) to 47.4 (44.3-50.5), whereas in the placebo group, scores decreased from 43.2 (95% CI, 40.2-46.3) to 39.9 (95% CI, 36.2-43.6), for a treatment benefit of 4.3 (95% CI, 0.4 to 8.3) (P = .03). There was no difference between groups (mean difference of 1.0 unit; 95% CI, –0.3 to 2.3; P = .14), for improvement in the Berg Balance Test, which improved by 2.2 units (95% CI, 1.3-3.1) in the deutetrabenazine group and by 1.3 units (95% CI, 0.4-2.2) in the placebo group. Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety, and akathisia. Conclusions and Relevance Among patients with chorea associated with Huntington disease, the use of deutetrabenazine compared with placebo resulted in improved motor signs at 12 weeks. Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety